144 related articles for article (PubMed ID: 2283256)
1. Tolerance of extracellular contrast agents for magnetic resonance imaging.
Weinmann HJ; Press WR; Gries H
Invest Radiol; 1990 Sep; 25 Suppl 1():S49-50. PubMed ID: 2283256
[No Abstract] [Full Text] [Related]
2. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat.
Cohan RH; Leder RA; Herzberg AJ; Hedlund LW; Wheeler CT; Beam CA; Nadel SN; Dunnick NR
Invest Radiol; 1991 Mar; 26(3):224-6. PubMed ID: 2055727
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
Evill CA; Wilson AJ; Fletcher MC; Sage MR
Acad Radiol; 1996 Aug; 3 Suppl 2():S336-8. PubMed ID: 8796597
[No Abstract] [Full Text] [Related]
4. Advances in macrocyclic gadolinium complexes as magnetic resonance imaging contrast agents.
Meyer D; Schaefer M; Doucet D
Invest Radiol; 1990 Sep; 25 Suppl 1():S53-5. PubMed ID: 2132570
[No Abstract] [Full Text] [Related]
5. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging.
Lauffer RB; Parmelee DJ; Ouellet HS; Dolan RP; Sajiki H; Scott DM; Bernard PJ; Buchanan EM; Ong KY; Tyeklár Z; Midelfort KS; McMurry TJ; Walovitch RC
Acad Radiol; 1996 Aug; 3 Suppl 2():S356-8. PubMed ID: 8796603
[No Abstract] [Full Text] [Related]
6. Chronic cisplatin nephropathy, contrast media, and creatinine.
Thomsen HS; Dorph S; Larsen S; Horn T; Hemmingsen L; Skaarup P; Golman K; Svendsen O
Acad Radiol; 1996 Aug; 3 Suppl 2():S444-6. PubMed ID: 8796625
[No Abstract] [Full Text] [Related]
7. Development of contrast media for magnetic resonance imaging.
Goldstein HA; Wiggins JR; Kashanian F
Ann N Y Acad Sci; 1992 Mar; 649():322-31. PubMed ID: 1580503
[No Abstract] [Full Text] [Related]
8. New magnetic resonance imaging contrast agents for infarct imaging based on phosphonate derivatives of Gd-DTPA.
Adzamli IK; Blau M; Pfeffer MA; Davis MA
Invest Radiol; 1991 Nov; 26 Suppl 1():S242-4; discussion S245-7. PubMed ID: 1808139
[No Abstract] [Full Text] [Related]
9. Paramagnetic liposomes as magnetic resonance contrast agents.
Unger E; Tilcock C; Ahkong QF; Fritz T
Invest Radiol; 1990 Sep; 25 Suppl 1():S65-6. PubMed ID: 2283260
[No Abstract] [Full Text] [Related]
10. The synthesis and screening of nonionic gadolinium (III) DTPA-bisamide complexes as magnetic resonance imaging contrast agents.
Periasamy M; White D; deLearie L; Moore D; Wallace R; Lin W; Dunn J; Hirth W; Cacheris W; Pilcher G
Invest Radiol; 1991 Nov; 26 Suppl 1():S217-20; discussion S232-5. PubMed ID: 1667003
[No Abstract] [Full Text] [Related]
11. An experimental study on the neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia.
La Noce A; Miragoli L; Samuelli G; Tirone P
Invest Radiol; 1996 Sep; 31(9):550-5. PubMed ID: 8877491
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of nonionic paramagnetic metal complexes as potential magnetic resonance imaging contrast agents.
White DH; Rajagopalan R; Kuan KT; Lin Y; Wallace RA; Rogic MM; Bosworth ME; Robbins MS; Ralston WH; Adams MD
Invest Radiol; 1990 Sep; 25 Suppl 1():S56-7. PubMed ID: 2126534
[No Abstract] [Full Text] [Related]
13. Quantification of liver capillary permeability using a macromolecular contrast agent for magnetic resonance imaging.
Clément O; Vuillemin-Bodaghi V; Cuénod CA; Siauve N; Blustajn J; Frija G
Acad Radiol; 1996 Aug; 3 Suppl 2():S342-3. PubMed ID: 8796598
[No Abstract] [Full Text] [Related]
14. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart.
Akre BT; Dunkel JA; Hustvedt SO; Refsum H
Acad Radiol; 1997 Apr; 4(4):283-91. PubMed ID: 9110026
[TBL] [Abstract][Full Text] [Related]
15. The functional effects of gadolinium-DTPA on the isolated perfused rat kidney.
Brown PW; Haylor JL; Morcos SK; el Nahas AM
Eur J Radiol; 1993 Feb; 16(2):85-9. PubMed ID: 8462585
[TBL] [Abstract][Full Text] [Related]
16. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium.
Berthezène Y; Mühler A; Lang P; Shames DM; Clément O; Rosenau W; Kuwatsuru R; Brasch RC
J Magn Reson Imaging; 1993; 3(1):125-30. PubMed ID: 8428078
[TBL] [Abstract][Full Text] [Related]
17. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
18. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
[TBL] [Abstract][Full Text] [Related]
19. Experimental approach to the intra-arterial magnetic resonance imaging contrast media (Gd-DTPA-iodized oil) and new lipophilic gadolinium complex combined with iodized oil.
Yoshikawa K; Shiono T; Yamashita T; Iwai H; Abe O; Hisamatsu K; Takenaka E
Invest Radiol; 1994 Jun; 29 Suppl 2():S245-6. PubMed ID: 7928246
[No Abstract] [Full Text] [Related]
20. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients.
Haustein J; Laniado M; Niendorf HP; Louton T; Beck W; Planitzer J; Schöffel M; Reiser M; Kaiser W; Schörner W
Radiology; 1993 Mar; 186(3):855-60. PubMed ID: 8430199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
